Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody drug conjugates
Biotech
AstraZeneca drops MASH drug over disappointing data
AstraZeneca has ended work on one of its drugs for fatty liver disease after viewing disappointing data from a phase 2 study.
James Waldron
Nov 6, 2025 5:21am
ESMO: AstraZeneca data 'validate' focus on in-house ADCs
Oct 18, 2025 12:55pm
ESMO: BMS believes ADC data allow it to 'stay ahead' of rivals
Oct 17, 2025 10:30am
French antibody biotech draws in $122M for push to clinic
Oct 16, 2025 11:19am
CDMO Catalent strengthens ADC pipeline with $10M Lisata pact
Oct 9, 2025 7:45am
Turbine looks to turbocharge AstraZeneca's ADC discovery
Oct 9, 2025 6:00am
